Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429945 | 0.81 | MAPK1 (0.39) | KDM4EMAPK1HPGDLMNATP53 | |
| SCHEMBL692975 | 0.79 | MAPK1 (0.43) | KDM4EMAPK1HPGDLMNATP53 | |
| SCHEMBL22439859 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9683574 | 0.79 | LMNA (0.36) | KDM4ELMNAL3MBTL1ADORA3 | |
| SCHEMBL16598893 | 0.78 | GABRP (0.48) | KDM4EMAPK1ALDH1A1HSD17B10NPSR1 | |
| SCHEMBL16598088 | 0.77 | MAPT (0.36) | KDM4EMAPK1LMNAMAPTALDH1A1 | |
| SCHEMBL25373403 | 0.76 | PLAT (0.36) | MAPK1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL6100678 | 0.76 | MAPK1 (0.43) | KDM4EMAPK1HPGDLMNAMAPT | |
| SCHEMBL162480 | 0.76 | MAPK1 (0.43) | KDM4EMAPK1TP53MAPTALDH1A1 | |
| SCHEMBL31741484 | 0.74 | MAPK1 (0.42) | KDM4EMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119451948-A | Pyridone compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023215775-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215775-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11225471-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210094938-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-04-01 | — | — | US | disclosed |
| EP-3709995-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-5811428-A | ADMINISTERING FOR THE TREATMENT AND PREVENTION OF IMMUNOINFLAMMATORY AND AUTOIMMUNE DISEASES | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0850228-A1 | PYRIMIDINE CARBOXAMIDES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997009315-A1 | PYRIMIDINE CARBOXAMIDES AND RELATED COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225471-B2 | Antidiabetic bicyclic compounds | GPR119, GPR65, GLP1R | KDM4E 3842/4885MAPK1 1510/4885HPGD 2581/4885 |
| US-20210094938-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | KDM4E 3842/4885MAPK1 1510/4885HPGD 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.